Could future advances in nanomedicine bring a breakthrough in genetic life extension?
In 2008, pharmaceutical giant GlaxoSmithKline announced that it would acquire all outstanding shares of Sirtris Pharmaceuticals for $720 million in order to cash in on the life-extending promise of resveratrol-based compounds, found in redgrapes and wine, which have been credited with extending life span. This thing is on clinical trial and various projects of similar intent are being conducted. I would recommend Dr. David Ewing Duncan’s statement on this futuristic breakthrough expected to materialise in the next 10 yrs but still with the likelihood of failure. The trial has shown encouraging signs on various experiments including one on mice, with high efficacy in slowing down the rate we age.
Complete video at: http://fora.tv/2008/07/15/Creative_Disruptions_David_Ewing_Duncan David Ewing Duncan, co-host of NPR\’s \